The Role of Neutrophil Elastase Inhibitors in Lung Diseases
The Role of Neutrophil Elastase Inhibitors in Lung Diseases
复制标题
DOI：
10.1016/j.chest.2017.03.056
复制
发表时间：
2017-08-01
期刊：
影响因子：
9.6
通讯作者：
Torres, Antoni
中科院分区：
文献类型：
--
作者：
Polverino, Eva;Rosales-Mayor, Edmundo;Torres, Antoni
在许多以强烈炎症反应为特征的呼吸道疾病中，蛋白水解酶（蛋白酶，包括弹性蛋白酶）及其抑制剂（蛋白酶抑制剂）之间的平衡不是中性的。据报道，中性粒细胞弹性蛋白酶（NE）和类似蛋白酶的过度活性在许多临床病症如肺炎、呼吸窘迫和急性肺损伤（ALI）中引起组织损伤并改变重塑过程。几种实验性NE抑制剂已在不同炎性肺损伤条件（如ALI和肺炎）的临床前和临床研究中进行了测试，结果截然不同。本研究回顾了有关NE抑制剂在呼吸系统疾病领域的文献，并反映了未来可能的发展。特别是，我们强调了科学证据中的潜在差距，并讨论了通过选择目标人群和适当的结果在临床实践中重点研究抗弹性蛋白酶的潜在策略。
In many respiratory diseases characterized by an intense inflammatory response, the balance between proteolytic enzymes (proteases, including elastases) and their inhibitors (proteinases inhibitors) is not neutral. Excess activity of neutrophil elastase (NE) and similar proteases has been reported to cause tissue damage and to alter the remodeling process in many clinical conditions such as pneumonia, respiratory distress, and acute lung injury (ALI). Several experimental NE inhibitors have been tested in preclinical and clinical studies of different conditions of inflammatory lung injury such as ALI and pneumonia, with contrasting results. This study reviews the literature regarding NE inhibitors in the field of respiratory diseases and reflects on possible future developments. In particular, we highlight potential gaps in the scientific evidence and discuss potential strategies for focusing investigation on antielastases in clinical practice through the selection of targeted populations and proper outcomes.